New Medicaid Bulletin Articles Available as of July 18
The NC Division of Health Benefits (DHB) has recently published new Medicaid Bulletin articles:
- Pegfilgrastim-pbbk injection, for Subcutaneous Use (Fylnetra®) HCPCS Code Q5130 - Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg: Billing Guidelines - Effective with date of service May 15, 2023, NC Medicaid covers pegfilgrastim-pbbk injection, for subcutaneous use (Fylnetra).
- Paclitaxel Protein-bound Particles for Injectable Suspension, (albumin-bound), for Intravenous Use (HBT Labs) HCPCS Code J9999 - Not Otherwise Classified, Antineoplastic Drug - Effective with date of service April 21, 2023, NC Medicaid covers paclitaxel protein-bound particles for injectable suspension, (albumin-bound).
- July Tailored Care Management Provider Manual Update - Updates include updated policies on Acuity Tiers, Acuity-Based Contacts and Contact Monitoring.
- Bevacizumab-adcd Injection, for Intravenous Use (Vegzelma®) HCPCS Code Q5129 - Injection, Bevacizumab-adcd (vegzelma), Biosimilar, 10 mg: Billing Guidelines - Effective with date of service April 17, 2023, NC Medicaid covers bevacizumab-adcd injection, for intravenous use (Vegzelma)
- Aripiprazole Extended-release Injectable Suspension, for Intramuscular Use (Abilify Asimtufii®) HCPCS Code J3490 - Unclassified Drugs: Billing Guidelines - Effective May 30, 2023, NC Medicaid covers aripiprazole extended-release injectable suspension, for intramuscular use (Abilify Asimtufii).
Providers are encouraged to review this information. All bulletin articles, including those related to COVID-19, are available on DHB's Medicaid Bulletin webpage.